The US Patent Trial and Appeal Board (PTAB) has instituted an inter partes review of US Patent No. 9,211,253, "Nasal drug products and methods of their use." That patent, which covers Opiant Pharmaceutical's Narcan intranasal naloxone for the reversal of opioid overdose through 2035, was granted to Lightlake Therapeutics (now Opiant) in December 2015. Adapt … [Read more...] about US Patent Trial and Appeal Board grants inter partes review of Narcan patent
Business
Hikma acquires naloxone and epinephrine nasal sprays from Insys
Hikma Pharmaceuticals has agreed to acquire two nasal sprays as well as unit-dose nasal spray manufacturing assets from Insys Therapeutics, the company said. In June 2019, Insys declared bankruptcy and said that it would sell all of its assets. Hikma did not say how much it paid for the naloxone and epinephrine nasal sprays. Insys announced results from a dose … [Read more...] about Hikma acquires naloxone and epinephrine nasal sprays from Insys
Perrigo and Endo settle suit over Nascobal nasal spray
Perrigo announced that it has settled a lawsuit filed by Endo Pharmaceuticals in May 2019 that alleged infringement of patents related to Nascobal cyanocobalamin nasal spray which expire in 2024. The terms of the settlement were not disclosed. Perrigo Executive VP and President, Rx Pharmaceuticals Sharon Kochan said, "This settlement is another example of our … [Read more...] about Perrigo and Endo settle suit over Nascobal nasal spray
Third Pole Therapeutics gets US patents for inhaled nitric oxide delivery systems
Third Pole Therapeutics said that it has received two new patents from the US Patent and Trademark Office covering its inhaled nitric oxide (iNO) delivery systems through at least 2038. The patents (No. 10,286,176 and No. 10,328,228) are titled "Systems and Methods for Generating Nitric Oxide" and "Systems and Methods for Ambulatory Generation of Nitric … [Read more...] about Third Pole Therapeutics gets US patents for inhaled nitric oxide delivery systems
Pulmatrix gets another US patent for iSPERSE formulations
The United States Patent and Trademark Office has granted US patent No. 10376465 ("Monovalent Metal Cation Dry Powders for Inhalation") to Pulmatrix, the company said. The claims cover formulations of Pulmazole inhaled dry powder itraconazole, which is based on Pulmatrix's iSPERSE particle engineering technology. Earlier this year, Pulmatrix announce that it had … [Read more...] about Pulmatrix gets another US patent for iSPERSE formulations
Alvogen to distribute Alvesco ciclesonide MDI in Central European countries
Alvogen has acquired marketing rights to the Alvesco cliclesonide metered dose inhaler in a number of Central and Eastern European (CEE) countries from Covis Pharma, the company said. Terms of the deal, which includes Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Poland, Romania, Russia and Slovakia, were not disclosed. In November 2018, Covis announced … [Read more...] about Alvogen to distribute Alvesco ciclesonide MDI in Central European countries
One Drop to integrate MannKind’s BluHale inhaler monitoring device for Afrezza
The One Drop diabetes management platform has agreed to integrate MannKind’s BluHale inhaler monitoring device for the Afrezza insulin DPI, the companies said. The integration of the BluHale device will allow for monitoring of insulin doses, glucose forecasts, and other services for patients using the Afrezza inhaler. MannKind Corporation CEO Michael Castagna … [Read more...] about One Drop to integrate MannKind’s BluHale inhaler monitoring device for Afrezza
Italfarmaco to develop inhaled teicoplanin for the treatment of MRSA infections in CF patients
Italfarmaco has announced that it will pay Neupharma "a total sum up to double digits in USD millions, excluding royalties" for an exclusive option to acquire global development and commercialization rights to inhaled teicoplanin for the treatment methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The inhaled teicoplanin … [Read more...] about Italfarmaco to develop inhaled teicoplanin for the treatment of MRSA infections in CF patients
Mylan to acquire TOBI manufacturing facility
A spokesperson for Novartis has confirmed to OINDPnews that Mylan exercised an option to acquire a San Carlos, CA, USA manufacturing facility for TOBI inhaled tobramycin products in May 2019 and is expected to acquire the site assets in September 2019. Mylan paid approximately $463 million to Novartis for worldwide rights to TOBI Podhaler DPI and TOBI inhalation … [Read more...] about Mylan to acquire TOBI manufacturing facility
Zambon acquires Breath Therapeutics
Italian pharmaceutical company Zambon announced that it has paid €140 million up front for Breath Therapeutics, which is developing L‑CsA‑i inhaled liposomal Cyclosporine A for the treatment of bronchiolitis obliterans syndrome (BOS). The deal includes regulatory and sales milestones that could bring the total up to €500 million. Breath Therapeutics is a spin off … [Read more...] about Zambon acquires Breath Therapeutics